遺傳基因編輯相關共同研究及授權契約:2016年～2025年

本報告全面解讀了全球領先生物製藥公司簽署的基因編輯協議，並提供了前所未有的存取權限。

本報告詳細解讀並分析了公司簽訂基因編輯協議的方式和原因。這些協議通常涉及多個方面，通常從合作研發開始，直到成果商業化。

合作協議涵蓋各種類型的合作協議，包括合作研發、開發和授權協議。

本報告提供了自2016年以來已宣布的384項基因編輯協議的完整列表，並儘可能包含財務條款。此外，報告還提供了每項協議的在線記錄鏈接，方便您參考實際公開的協議。此外，記錄中還包含公司和/或合作夥伴向美國證券交易委員會 (SEC) 提交的合約文件（如有）。

主要優勢：

• 了解自2016年以來的交易趨勢
• 查看基因編輯合作與授權協議
• 基準分析：確定交易的市場價值
• 詳細的財務條款：預付款、里程碑付款、特許權使用費
• 按公司名稱（A-Z）、交易類型和治療領域排序的交易目錄
• 按價值排序的熱門交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和條款
• 存取合約文件：深入了解合約結構
• 盡職調查：評估擬議合約條款是否適合您的合作夥伴
• 節省數百小時的研究時間

合約分析可讓您對以下內容進行盡職調查：

• 具體授予或選擇哪些權利？
• 合約實際上賦予了合作夥伴什麼？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？ （總價款、里程碑付款、特許權使用費等）
• 如何審計銷售和付款？
• 合約期間（生效期間）是多久？
• 合約的主要條款是如何界定的？
• 如何處理知識產權 (IPR)，歸誰所有？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和成果揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果公司所有權發生變化，合約會怎樣？
• 如何約定再授權和分包條款？
• 公司通常會包含哪些 "範本條款" ？
• 根據合約當事人和合約類型，有哪些 "範本條款" ？
• 公司要求哪個司法管轄區作為合約法下的準據法？

目錄

摘要整理

第1章 簡介

第2章 遺傳基因編輯相關契約動向

• 各年度的遺傳基因編輯契約數量
• 最活躍的契約締結企業
• 遺傳基因編輯契約:各類型契約
• 遺傳基因編輯契約:各治療領域
• 遺傳基因編輯契約:各業界
• 遺傳基因編輯交易的交易條件

第3章 主要遺傳基因編輯契約

• 主要遺傳基因編輯契約:契約各金額

第4章 最活躍的遺傳基因編輯契約締結企業

• 最活躍的遺傳基因編輯契約締結企業
• 最活躍的遺傳基因編輯契約締結企業簡介

第5章 遺傳基因編輯契約的交易名錄

• 遺傳基因編輯契約的交易名錄

第6章 遺傳基因編輯契約:各技術類型

• 契約名錄
• 契約名錄- 各企業 (A-Z)
• 契約名錄- 各類型契約
• 契約名錄- 各治療領域
• 契約類型定義
• 關於Biopharma Research Ltd
• 目前聯盟
• 目前契約
• Current Partnering最近的報告標題

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 384 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
• Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity - 2016 - 2025
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers 2016 - 2025
• Figure 12: Gene editing deals by technology type since 2016